title: Gene expression analysis of microtubule affinity-regulating kinase 2 in non-small cell lung cancer.
abstract: Lung cancer is the leading cause of cancer death worldwide, and has a five-year survival rate of 18% [1]. MARK2 is a serine/threonine-protein kinase, and is a key component in the phosphorylation of microtubule-associated proteins [2], [3]. A recent study published by Hubaux et al. found that microtubule affinity-regulating kinase 2 (MARK2) showed highly frequent DNA and RNA level disruption in lung cancer cell lines and independent non-small cell lung cancer (NSCLC) cohorts [4]. These alterations result in the acquisition of oncogenic properties in cell lines, such as increased viability and anchorage-independent growth. Furthermore, a microarray-based transcriptome analysis of three short hairpin RNA (shRNA)-mediated MARK2 knockdown lung adenocarcinoma cell lines (GEO#: GSE57966) revealed an association between MARK2 gene expression and cell cycle activation and DNA damage response. Here, we present a detailed description of transcriptome analysis to support the described role of MARK2 in promoting a malignant phenotype.
authors.affiliation: Department of Integrative Oncology, BC Cancer Agency, Vancouver, Canada.
authors.forename: Erin A
authors.initials: EA
authors.lastname: Marshall
authors.affiliation: Department of Integrative Oncology, BC Cancer Agency, Vancouver, Canada.
authors.forename: Kevin W
authors.initials: KW
authors.lastname: Ng
authors.affiliation: Department of Integrative Oncology, BC Cancer Agency, Vancouver, Canada.
authors.forename: Christine
authors.initials: C
authors.lastname: Anderson
authors.affiliation: Department of Integrative Oncology, BC Cancer Agency, Vancouver, Canada.
authors.forename: Roland
authors.initials: R
authors.lastname: Hubaux
authors.affiliation: Department of Integrative Oncology, BC Cancer Agency, Vancouver, Canada.
authors.forename: Kelsie L
authors.initials: KL
authors.lastname: Thu
authors.affiliation: Department of Integrative Oncology, BC Cancer Agency, Vancouver, Canada.
authors.forename: Wan L
authors.initials: WL
authors.lastname: Lam
authors.affiliation: Department of Integrative Oncology, BC Cancer Agency, Vancouver, Canada.
authors.forename: Victor D
authors.initials: VD
authors.lastname: Martinez
keywords: Affymetrix; Gene set enrichment analysis; Lung cancer; MARK2; Microarray